POZEN Inc. announced that James P. Tursi, M.D. will be appointed Chief Medical Officer of POZEN, effective October 1, 2015. Dr. Tursi will report to Adrian Adams, Chief Executive Officer of POZEN, and will be responsible for the oversight of the clinical operations, drug safety, medical and regulatory affairs functions. Dr. Tursi will also become Chief Medical Officer of Aralez Pharmaceuticals upon the anticipated business combination among Aralez, POZEN and Tribute Pharmaceuticals Canada Inc. He will play a critical role in the planned preparation of the re-submission of the YOSPRALA New Drug Application (NDA) in the United States, the Marketing Authorization Application (MAA) for YOSPRALA in Europe and the New Drug Submissions (NDS) for YOSPRALA and MT400 to Health Canada.

Dr. Tursi will also serve on the executive leadership team. Dr. John G. Fort will serve as Chief Scientific Advisor until the middle of next year. Dr. James Tursi has over 11 years of extensive experience developing pharmaceuticals across a number of therapeutic areas.

Most recently he served as Chief Medical Officer of Innocoll AG where he was responsible for managing all clinical research and development, medical affairs and safety activities.